FDA Inspection
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA Inspection, Mar 14, 2022
Record Details
This FDA Inspection record concerns Bristol-Myers Squibb Company, with an inspection on March 14, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Bristol-Myers Squibb Company
- Inspection Date
- March 14, 2022
- Product Type
- Drugs
View Company Profile
ID · 3425021c-e05a-405a-b49d-269fd28c5388
Inspection Facts
No Action Indicated (NAI)
No objectionable conditions or practices were found during the inspection.
- Inspection number
- 1165563
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
Other FDA inspections of Bristol-Myers Squibb Company
16| Date | Classification | Office | Project area |
|---|---|---|---|
| June 23, 2026 | Not classified | New Jersey District Office | |
| July 18, 2025 | Not classified | New Jersey District Office | |
| December 6, 2024 | VAI | New Jersey District Office | Postmarketing Surveillance and Epidemiology: Human Drugs |
| September 6, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| January 31, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Bristol-Myers Squibb Company
- FDA Inspection 1327472 - 2026-06-23
- FDA Inspection 1275526 - 2025-07-18
- FDA Inspection 1236864 - 2024-12-06
- FDA Inspection 1247735 - 2024-09-06
- FDA Inspection 1228973 - 2024-01-31
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.